• 1. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 2. Excimer formation effects and trap-assisted charge recombination loss channels in organic solar cells of perylene diimide dimer acceptors?
  Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696
• 3. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 4. Exchanged ligands on the surface of a giant cluster: [(MoO3)176(H2O)63(CH3OH)17Hn](32 – n)–
  Chem. Commun., 1998, 1501-1502
• 5. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212

Research Brief on 2-cyclohexyl-1-(pyrimidin-2-yl)ethan-1-one (CAS: 1249454-39-4) in Chemical Biology and Pharmaceutical Applications

The compound 2-cyclohexyl-1-(pyrimidin-2-yl)ethan-1-one (CAS: 1249454-39-4) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This research brief aims to synthesize the latest findings on this compound, focusing on its synthesis, biological activity, and relevance in drug discovery.

Recent studies have highlighted the role of 2-cyclohexyl-1-(pyrimidin-2-yl)ethan-1-one as a key intermediate in the synthesis of novel kinase inhibitors. Its pyrimidine moiety, coupled with the cyclohexyl group, provides a versatile scaffold for modulating protein-ligand interactions, particularly in targeting ATP-binding sites of kinases. A 2023 study published in the Journal of Medicinal Chemistry demonstrated its efficacy in inhibiting cyclin-dependent kinases (CDKs), which are critical targets in cancer therapy.

In addition to its kinase inhibitory properties, this compound has shown promise in the development of antimicrobial agents. Research conducted at the University of Cambridge revealed that derivatives of 2-cyclohexyl-1-(pyrimidin-2-yl)ethan-1-one exhibit potent activity against drug-resistant bacterial strains, including methicillin-resistant Staphylococcus aureus (MRSA). The mechanism of action appears to involve disruption of bacterial cell wall synthesis, as evidenced by in vitro assays and molecular docking studies.

From a synthetic chemistry perspective, advancements in the preparation of 2-cyclohexyl-1-(pyrimidin-2-yl)ethan-1-one have been reported. A 2024 paper in Organic Letters detailed a novel, high-yield synthetic route utilizing palladium-catalyzed cross-coupling reactions, which significantly improves the scalability and purity of the compound. This methodological innovation is expected to facilitate further pharmacological investigations and preclinical development.

Despite these promising findings, challenges remain in optimizing the pharmacokinetic properties of 2-cyclohexyl-1-(pyrimidin-2-yl)ethan-1-one derivatives. Current research efforts are focused on enhancing bioavailability and reducing off-target effects through structural modifications. Collaborative studies between academic and industrial researchers are underway to address these limitations and accelerate the translation of this compound into clinical candidates.

In conclusion, 2-cyclohexyl-1-(pyrimidin-2-yl)ethan-1-one (CAS: 1249454-39-4) represents a valuable chemical entity with diverse applications in drug discovery. Its dual role as a kinase inhibitor and antimicrobial agent underscores its potential in addressing unmet medical needs. Continued research into its mechanism of action and derivative optimization will be crucial for realizing its full therapeutic potential.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)